MRUS - Merus

-

$undefined

N/A

(N/A)

Merus NasdaqGM:MRUS Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Location: Uppsalalaan 17, Utrecht, 3584 CT, Netherlands | Website: https://www.merus.nl | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

2.428B

Cash

458.3M

Avg Qtr Burn

-59.48M

Short % of Float

10.68%

Insider Ownership

1.85%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
BIZENGRI® (zenocutuzumab-zbco) Details
Cancer, Solid tumor/s, Non-small cell lung carcinoma, Pancreatic cancer

Approved

Quarterly sales

Petosemtamab (MCLA-158) +/- Keytruda (pembrolizumab) Details
Head and neck squamous cell carcinoma

Susp. Mover™

Phase 2/3

Data readout

Petosemtamab (MCLA-158) (Lgr5 x EGFR Biclonics®) Details
Solid tumor/s, Cancer, Metastatic colorectal cancer

Phase 2

Data readout

Phase 2

Data readout

Petosemtamab (MCLA-158) (Lgr5 x EGFR Biclonics®) in comb w/ SoC Details
Solid tumor/s, Cancer, Metastatic colorectal cancer

Phase 2

Data readout

MCLA-129 (EGFR x c-MET Biclonics®) + Osimertinib Details
Solid tumor/s, Cancer, Non-small cell lung carcinoma

Phase 1/2

Data readout

Phase 1

Update